---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-063151"
form_type: "8-K"
ticker: "BZYR"
cik: "0000724445"
company_name: "BURZYNSKI RESEARCH INSTITUTE INC"
filed_at: "2023-05-22T23:59:59+00:00"
generated_at: "2026-06-14T18:47:41.587008+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BZYR licenses antineoplaston patents from CEO; research funding secured through Feb 2024

## Summary
- License from Dr. Burzynski for exclusive rights to four US patents and pending applications for antineoplastons in US/Canada.
- Research Funding Agreement: Dr. Burzynski funds all basic research and FDA-related trial costs; term to Feb 2024, auto-renewable.
- Amended Royalty and Research Funding Agreements limited to US/Canada scope.
- License can terminate if Burzynski removed as officer/director or if another party equals his voting power.

## SEC filing metadata
- accession: 0001104659-23-063151
- form_type: 8-K
- ticker: BZYR
- cik: 0000724445
- company_name: BURZYNSKI RESEARCH INSTITUTE INC
- filed_at: 2023-05-22T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/724445/000110465923063151/0001104659-23-063151-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/724445/000110465923063151/tm2316366d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-063151
- JSON: https://secwatch.observer/filing/0001104659-23-063151.json
- Plain text: https://secwatch.observer/filing/0001104659-23-063151.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.